Fatma M. Abdelwahed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatma M. Abdelwahed has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Heba Effat
Medical Biochemistry and Molecular Biology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt
2 shared publications Marwa A. Ibrahim
Medicinal and Aromatic plants Department, Desert Research Center, Cairo, Egypt
2 shared publicationsMarwa Sharaky
Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt
1 shared publication- Nadine W. Maurice
Department of Biochemistry, Faculty of Pharmacy, Cairo University, Kasr El Aini St., Cairo, Egypt
1 shared publication - Osama Ahmed Badary
Department of Clinical pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
1 shared publication Rehab S. Abohashem
Hormones Department, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Isatin-mediated inhibition of the PI3K/AKT/EMT signaling axis confers antitumor efficacy in Ehrlich solid carcinoma-bearing mice
Despite advances, detailed insight into cancer’s biological mechanisms remains needed. Isatin, an indole-1 H-2,3-dione, is an attractive age
- 28 May 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessIsatin-mediated inhibition of the PI3K/AKT/EMT signaling axis confers antitumor efficacy in Ehrlich solid carcinoma-bearing mice
Despite advances, detailed insight into cancer’s biological mechanisms remains needed. Isatin, an indole-1 H-2,3-dione, is an attractive age
- 10 December 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (12) , 6214-6227
Isatin, a monoamine oxidase inhibitor, sensitizes resistant breast cancer cells to tamoxifen via MAO-A/HIF1α/MMPs modulation
Isatin enhances the anticancer activity of tamoxifen in resistant breast cancer cells by inhibiting MAO-A, inducing apoptosis and overcoming drug resistance.
- 10 December 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (12) , 6214-6227
Isatin, a monoamine oxidase inhibitor, sensitizes resistant breast cancer cells to tamoxifen via MAO-A/HIF1α/MMPs modulation
Isatin enhances the anticancer activity of tamoxifen in resistant breast cancer cells by inhibiting MAO-A, inducing apoptosis and overcoming drug resistance.
- Open Access
- 14 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15904
Thymoquinone Suppresses Angiogenesis in DEN-Induced Hepatocellular Carcinoma by Targeting miR-1-3p
Hepatocellular carcinoma (HCC) is characterized by its high vascularity and metastasis. Thymoquinone (TQ), the main bio-active constituent of Nigella sativa, has shown anticancer and hepatoprotective effects. TQ’s anticancer effect is mediated through miRNA regulation. miR-1-3p plays a significant role in various cancers but its role in HCC invasiveness remains poorly understood. Bio-informatics analysis predicted that the 3′-UTR of TIMP3 is a target for miR-1-3p; Rats were equally divided into four groups: Group 1, the negative control; Group 2 received TQ; Group 3 received DEN; and Group 4 received DEN after pretreatment with TQ. The expression of TIMP3, MMP2, MMP9, and VEGF in rats’ liver was determined immunohistochemically. RT-qPCR was used to measure the miR-1-3p level in rats’ liver, and TIMP3, MMP2, MMP9, and VEGF in the HepG2 cells after being transfected with miR-1-3p mimic or inhibitor; In rats pretreated with TQ, a decreased expression of MMP2, MMP9 and VEGF, and increased expression levels of TIMP3 and miR-1-3p were detected. Treating the HepG2 cells with miR-1-3p mimic led to the upregulation of TIMP3 and downregulation of MMP2, MMP9, and VEGF, and showed a significant delay in wound healing; These results suggested that the anti-angiogenic effect of TQ in HCC may be mediated through the regulation of miR-1-3p.
- 14 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15904
Open AccessThymoquinone Suppresses Angiogenesis in DEN-Induced Hepatocellular Carcinoma by Targeting miR-1-3p
Hepatocellular carcinoma (HCC) is characterized by its high vascularity and metastasis. Thymoquinone (TQ), the main bio-active constituent of Nigella sativa, has shown anticancer and hepatoprotective effects. TQ’s anticancer effect is mediated through miRNA regulation. miR-1-3p plays a significant role in various cancers but its role in HCC invasiveness remains poorly understood. Bio-informatics analysis predicted that the 3′-UTR of TIMP3 is a target for miR-1-3p; Rats were equally divided into four groups: Group 1, the negative control; Group 2 received TQ; Group 3 received DEN; and Group 4 received DEN after pretreatment with TQ. The expression of TIMP3, MMP2, MMP9, and VEGF in rats’ liver was determined immunohistochemically. RT-qPCR was used to measure the miR-1-3p level in rats’ liver, and TIMP3, MMP2, MMP9, and VEGF in the HepG2 cells after being transfected with miR-1-3p mimic or inhibitor; In rats pretreated with TQ, a decreased expression of MMP2, MMP9 and VEGF, and increased expression levels of TIMP3 and miR-1-3p were detected. Treating the HepG2 cells with miR-1-3p mimic led to the upregulation of TIMP3 and downregulation of MMP2, MMP9, and VEGF, and showed a significant delay in wound healing; These results suggested that the anti-angiogenic effect of TQ in HCC may be mediated through the regulation of miR-1-3p.